Reduction of Pathogen Load From the Blood in Septic Patients With Suspected, Life-threatening Bloodstream Infection
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04260789 |
|
Recruitment Status :
Recruiting
First Posted : February 7, 2020
Last Update Posted : December 17, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Bloodstream Infection | Device: Seraph 100,The Microbind Affinity Blood Filter | Not Applicable |
With the lack of effective antibiotics for many bloodstream infections, and limited new anti-infectives in development, there is a significant unmet need for new approaches that can help treat drug-resistant infections, especially in patients at high risk. There is an unmet need for a safe and broad-spectrum hemoperfusion therapy that can quickly reduce bacterial load and shorten the duration of bacteremia, preferably without the need to first identifying the type of bacteria present in the blood. There is an emerging need to increase the efficacy of effective antibiotics, e.g., by using hemadsorption as adjunctive therapy, to by quickly reducing bacterial load while scavenging toxins released from bacteria. Finally, there is a medical growing need for an alternative therapy when no effective antibiotic is available.
Seraph 100 Microbind Affinity Blood Filter is used to reduce pathogen load during bloodstream infection. Bacteremia or bloodstream infection, also called BSI, occurs when a bacterial infection elsewhere in the body enters the bloodstream. This clinical condition can quickly become life-threatening and progress to sepsis. Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection (Singer et al., 2016).When sepsis occurs with extremely low blood pressure, it's called septic shock. Septic shock is fatal in many cases.
Sepsis can be triggered by many types of bacteremia although the exact source of the infection often cannot be determined. Some of the most common infections that lead to BSI are lung infections (i.e. pneumonia) and infections in the abdominal area. Patients who are already in the hospital for something else, such as a surgery, are at a higher risk of developing BSI. These infections are even more dangerous when the bacteria are already resistant to antibiotics. The National Institutes of Health (NIH) estimates that over 1 million Americans get sepsis each year. Between 28 and 50 percent of these patients may die from the condition.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 232 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Open randomized post-market trial |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Safety and Performance Evaluation of Seraph 100 Microbind Affinity Blood Filter (Seraph 100) in the Reduction of Pathogen Load From the Blood in Septic Patients With Suspected, Life-threatening Bloodstream Infection |
| Actual Study Start Date : | August 19, 2020 |
| Estimated Primary Completion Date : | March 1, 2022 |
| Estimated Study Completion Date : | August 1, 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Treatment
Treatment with Seraph Filter
|
Device: Seraph 100,The Microbind Affinity Blood Filter
Treatment with Seraph 100 in one arm |
| No Intervention: Control |
- Reduction of pathogens load [ Time Frame: 4,5 hours +/- 30 min ]Reduction of pathogens load from the bloodstream during treatment
- All-cause mortality [ Time Frame: 90 days ]All-cause mortality
- Persistence/Recurrence of bacteremia [ Time Frame: Day 1, day 2, day 7 ]Measure persistence recurrence of bacteremia
- Persistence/Recurrence of sepsis [ Time Frame: Daily during ICU stay or at least day 1, day 2, day 7 ]Measure persistence recurrence of sepsis
- Organ dysfunction-free days [ Time Frame: Daily during ICU stay or at least day 1, day 2, day 7 ]Measure organ dysfunction free days
- Change of Intensive Care Unit (ICU) complications [ Time Frame: Daily during ICU stay or at least day 1, day 2, day 7 ]Reduction of ICU complications
- Ventilator-free days (VFDs) [ Time Frame: Daily during ICU stay or at least day 1, day 2, day 7 ]VFD
- Length of stay (LOS) at ICU and hospital ward [ Time Frame: During ICU and hospital ward stay or at least day 1, day 2, day 7 ]Measure LOS
- Treatment emergent adverse events [ Time Frame: Occurrence within the 90 days follow-up period ]N (%) of patients with treatment emergent adverse events
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 90 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Patients with sepsis and suspected bloodstream infection
- Be ≥ 18 years old and ≤ 90 years old
- Adults receiving IV antibiotic therapy
- Increase of at least two points of the Sequential Organ Failure Assessment (SOFA) score
- Subjects that presents Procalcitonin (PCT) levels > 0,5 ng/mL
Exclusion Criteria:
- Subject is currently participating in another clinical investigation
- Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period
- Presence of comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results
- The first dose of the current antibiotic therapy was > 24 h before screening
- Have Child-Pugh Class C cirrhosis
- Have platelet count < 30.000/uL
- Contraindications for heparin sodium for injection
- Subjects demonstrating any contraindication for this treatment as described in the IFU
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04260789
| Contact: Carla Kikken-Jussen | +31438200399 | carla@extheramedical.com |
Show 25 study locations
| Principal Investigator: | Herwig Gerlach, Prof. | Vivantes Klinikum Neukölln |
| Responsible Party: | ExThera Medical Europe BV |
| ClinicalTrials.gov Identifier: | NCT04260789 |
| Other Study ID Numbers: |
CP015 |
| First Posted: | February 7, 2020 Key Record Dates |
| Last Update Posted: | December 17, 2021 |
| Last Verified: | December 2021 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Infections Communicable Diseases Sepsis Disease Attributes |
Pathologic Processes Systemic Inflammatory Response Syndrome Inflammation |